PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsBevacizumab
Avastin(bevacizumab)
Abevmy, Alymsys, Avastin, Avzivi, Aybintio, Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev (bevacizumab) is an antibody pharmaceutical. Bevacizumab was first approved as Lextemy on . It is used to treat colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, and non-small-cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, non-small-cell lung carcinoma, and ovarian neoplasms amongst others. The pharmaceutical is active against vascular endothelial growth factor A, long form. In addition, it is known to target Vascular permeability factor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Alymsys, Avastin, Jobevne, Mvasi, Vegzelma, Zirabev
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Bevacizumab
Tradename
Proper name
Company
Number
Date
Products
AvastinbevacizumabGenentechN-125085 RX2004-02-26
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
alymsysBiologic Licensing Application2022-04-27
avastinBiologic Licensing Application2025-01-06
avziviBiologic Licensing Application2024-10-09
jobevneBiologic Licensing Application2025-04-01
mvasiBiologic Licensing Application2025-06-23
vegzelmaBiologic Licensing Application2025-05-08
zirabevBiologic Licensing Application2025-08-05
Agency Specific
FDA
EMA
Expiration
Code
bevacizumab, Avastin, Genentech, Inc.
2027-05-29Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FG: Vegf/vegfr (vascular endothelial growth factor) inhibitors
L01FG01: Bevacizumab
S: Sensory organ drugs
S01: Ophthalmologicals
S01L: Ocular vascular disorder agents
S01LA: Antineovascularisation agents
S01LA08: Bevacizumab
HCPCS
Code
Description
C9257
Injection, bevacizumab, 0.25 mg
J9035
Injection, bevacizumab, 10 mg
Q5107
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5118
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
Clinical
Clinical Trials
3634 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517961621530
Hepatocellular carcinomaD006528C22.03101216
Liver neoplasmsD008113EFO_1001513C22.02101215
Macular edemaD00826946219
Retinal vein occlusionD012170EFO_1001157H34.811112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228910412349
Breast neoplasmsD001943EFO_0003869C505356348
NeoplasmsD009369C8010212132
Ovarian neoplasmsD010051EFO_0003893C567221130
Lung neoplasmsD008175C34.905223227
Neoplasm metastasisD009362EFO_0009708614320
Fallopian tube neoplasmsD0051854141120
Renal cell carcinomaD002292EFO_0000376192112
Pancreatic neoplasmsD010190EFO_0003860C2556111
Rectal neoplasmsD01200425129
Show 18 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515525129
GliomaD005910EFO_0000520617222
Brain neoplasmsD001932EFO_0003833C71416118
GliosarcomaD0183161414
Prostatic neoplasmsD011471C613910
Kidney neoplasmsD007680EFO_0003865C6411010
Stomach neoplasmsD013274EFO_0003897C1699
Esophageal neoplasmsD004938C1599
SarcomaD012509358
Head and neck neoplasmsD006258268
Show 79 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic footD017719EFO_100145911
Foot ulcerD01652311
Healthy volunteers/patients11
Radiation injuriesD011832T6611
Desmoplastic small round cell tumorD05840511
Neuromyelitis opticaD009471EFO_0004256G36.011
Diffuse intrinsic pontine gliomaD00008044311
Salivary gland neoplasmsD012468EFO_0003826D1111
Thyroid neoplasmsD013964EFO_000384111
Parotid neoplasmsD010307EFO_0003873C0711
Show 5 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Central nervous system neoplasmsD01654311
Anus neoplasmsD001005EFO_0003835C2111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBevacizumab
INNbevacizumab
Description
Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>7V5N:A,E|bevacizumab fab light chain DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >7V5N:B,F|bevacizumab fab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
Identifiers
PDB6BFT, 7V5N
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201583
ChEBI ID
PubChem CID
DrugBankDB00112
UNII ID2S9ZZM9Q9V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
Mouse ortholog
Variants
No data
Financial
Revenue by drug
$
£
Aybintio Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Avastin Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zirabev Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 722 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
126,883 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use